This despite the company's stated stand of no possible deal with Pfizer in the near future.
The company's share price touched a 52-weeks high on Monday on speculation that the global drug major, Pfizer, may buy stake or strike a marketing deal with the company.
However, it has been strongly denied by Biocon.
"We don't want to comment on speculation," a company spokesperson said.